SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following reported 700% year-over-year revenue growth, fueled by recent expanded global approvals for its cancer therapies in the EU and Saudi Arabia. The community is buzzing with anticipation of a significant short squeeze and further label expansions, highlighting the immense potential of its diverse immunotherapy platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after its CagriSema weight-loss drug trial achieved 23% weight loss but missed its primary endpoint of non-inferiority compared to Eli Lilly's tirzepatide, causing a significant stock drop. The community is debating whether this market reaction is an overblown response to a minor efficacy difference, creating a buying opportunity, or if it signals a tougher competitive landscape against its rival.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for BYSANTI, its new drug for bipolar I disorder and schizophrenia, a development the community sees as a significant re-rating catalyst due to its New Chemical Entity status and patent protection extending to 2044. This long-term exclusivity is fueling widespread speculation about potential buyout offers from major pharmaceutical companies and the stock's short squeeze potential, even as some investors eye commercial launch timelines and possible dilution.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors digest news of a significant stock sale filing from Trump's trust, fueling community discussions around potential dilution and the company's highly scrutinized financial viability. There is ongoing anticipation of upcoming reports and updates regarding a debated 'fusion deal' amidst concerns about its fundamental value.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Enthusiasm for MoonLake Immunotherapeutics is surging following stellar Phase 2 S-OLARIS trial results for its lead drug sonelokimab in axial spondyloarthritis, with the community highlighting "best-in-class" efficacy, disease-modifying potential, strong financials, and anticipating further positive updates at its upcoming Investor Day.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending as a recent direct stock offering at $5 sparks debate, with bulls viewing it as a strategic move to fund game-changing MST technology for AI and data centers, while bears voice skepticism over dilution given the company's pre-revenue status and historical performance.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx is trending as Gilead Sciences announced its acquisition for $7.8 billion, with the community focusing on the substantial premium and the strategic value of Arcellx's promising CAR T-cell therapy, anito-cel, which has shown strong clinical data for multiple myeloma.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its mainnet launch and institutional validation, including its Coinbase 50 index inclusion, drive bullish conviction in its utility and long-term potential, yet the community remains sharply divided amid persistent price drops leading to strong skepticism about the project's viability.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA granting Priority Review for AXS-05 in Alzheimer's disease agitation, setting an April PDUFA date, alongside robust Q4 earnings and strong commercial growth for its CNS therapies. The community is highly optimistic about AXS-05's market potential and the company's trajectory towards cash flow positivity, further supported by multiple analyst upgrades and pipeline advancements.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's recent obesity drug trial setback intensifies community speculation around a major acquisition or partnership, highlighting Viking's promising VK2735 asset as a crucial strategic fit for big pharma. Many believe the urgent need for a competitive GLP-1/GIP dual agonist in the booming metabolic market will force a significant deal and trigger a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Infinya Ltd. engages in the manufacture and marketing of writing and printing paper, packaging cartons, and in the collection and processing of waste paper. It operates through the following segments: Recycling, Paper Rolls for Carton, Carton Packaging. The Recycling segment engages in the processing and recycling of waste paper, waste carton, and plastic. The Paper Rolls for Carton segment engages in the sale of recycled paper rolls for cartons to companies engaging in the manufacture of carton packages. The Carton Packaging segment engages in the sale of carton packaging products for consumer goods. The company was founded in 1951, and is headquartered in Hadera, Israel.

HAIPF
Infinya Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest HAIPF News

HAIPFInfinya Ltd